Advanced searches left 3/3

Meperidine - Europe PMC

Summarized by Plex Scholar
Last Updated: 20 April 2022

* If you want to update the article please login/register

A hypothetical proposal to employ meperidine and tamoxifen in treatment of glioblastoma. Role of P-glycoprotein, ceramide and metabolic pathways.

Meperidine is a -opioid receptor agonist widely used in cancer pain treatment. Although MOR agonists in experimental studies have demonstrated both pro- and antitumorigenic properties, meperidine has specific characteristics that may be specifically anticancer in nature. Meperidine reduces cell proliferation around the neural tube in the newborn embryonic neural tissue and reduces the expression of the BRE in the developing embryonic neural tissue. Meperidine promotes cell death and reverses multidrug resistance by raising the pro-autophagic and pro-apoptotic ceramide levels in cancer cells. P-glycoprotein is directly blocked by P-glycoprotein blockage, and increased ceramide levels are achieved both via inhibition of glycosylceramide synthase and ceramidase. Tamoxifen, however, blocks NMDA-neurotoxicity, and so it may act synergistically with meperidine in lowering glioblastoma progression associated with NMDA-activation.

Source link: https://europepmc.org/article/MED/35316699


Comparison of dexmedetomidine and meperidine for the prevention of shivering following coronary artery bypass graft: study protocol of a randomised controlled trial.

shivering has been reported under general anaesthesia to as much as 65% and as much as 33% during epidural anaesthesia. Shivering can elevate patient risk during perioperative risk. Both dexmedetomidine and meperidine are safe agents for the prevention of postanaesthetic shivering. Following coronary artery bypass graft graft, however, no studies have compared the anti-shivering results of various drugs. This review aims to compare the effects of dexmedetomidine and meperidine on the incidence of shivering in patients undergoing CABG. Ethics and dissemination The study protocol was approved by the ethics committee of Shandong First Medical University's ethics committee on January 2021 and published on ClinicalTrials. gov on January 20, 2021.

Source link: https://europepmc.org/article/MED/35149565

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions